Recent advances and future directions in anti-tumor activity of cryptotanshinone: A mechanistic review
- PMID: 33507609
- DOI: 10.1002/ptr.6815
Recent advances and future directions in anti-tumor activity of cryptotanshinone: A mechanistic review
Abstract
In respect to the enhanced incidence rate of cancer worldwide, studies have focused on cancer therapy using novel strategies. Chemotherapy is a common strategy in cancer therapy, but its adverse effects and chemoresistance have limited its efficacy. So, attempts have been directed towards minimally invasive cancer therapy using plant derived-natural compounds. Cryptotanshinone (CT) is a component of salvia miltiorrihiza Bunge, well-known as Danshen and has a variety of therapeutic and biological activities such as antioxidant, anti-inflammatory, anti-diabetic and neuroprotective. Recently, studies have focused on anti-tumor activity of CT against different cancers. Notably, this herbal compound is efficient in cancer therapy by targeting various molecular signaling pathways. In the present review, we mechanistically describe the anti-tumor activity of CT with an emphasis on molecular signaling pathways. Then, we evaluate the potential of CT in cancer immunotherapy and enhancing the efficacy of chemotherapy by sensitizing cancer cells into anti-tumor activity of chemotherapeutic agents, and elevating accumulation of anti-tumor drugs in cancer cells. Finally, we mention strategies to enhance the anti-tumor activity of CT, for instance, using nanoparticles to provide targeted drug delivery.
Keywords: Danshen; cancer therapy; cryptotanshinone; herbal compounds; signaling pathway.
© 2020 John Wiley & Sons, Ltd.
References
REFERENCES
-
- Aggarwal, V., Tuli, H. S., Thakral, F., Singhal, P., Aggarwal, D., Srivastava, S., … Khan, M. A. (2020). Molecular mechanisms of action of hesperidin in cancer: Recent trends and advancements. Experimental Biology and Medicine, 1535370220903671. 245(5), 486-497.
-
- Altamirano, J., & Bataller, R. (2011). Alcoholic liver disease: Pathogenesis and new targets for therapy. Nature Reviews Gastroenterology & Hepatology, 8(9), 491-501.
-
- Alvarez-Quilon, A., Terron-Bautista, J., Delgado-Sainz, I., Serrano-Benitez, A., Romero-Granados, R., Martinez-Garcia, P. M., … Cortes-Ledesma, F. (2020). Endogenous topoisomerase II-mediated DNA breaks drive thymic cancer predisposition linked to ATM deficiency. Nature Communications, 11(1), 910. https://doi.org/10.1038/s41467-020-14638-w
-
- Alzahrani, A. S. (2019). PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. Seminars in Cancer Biology, 59, 125-132. https://doi.org/10.1016/j.semcancer.2019.07.009
-
- Anderson, K., Ryan, N., Volpedo, G., Varikuti, S., Satoskar, A. R., & Oghumu, S. (2019). Immune suppression mediated by STAT4 deficiency promotes lymphatic metastasis in HNSCC. Frontiers in Immunology, 10, 3095. https://doi.org/10.3389/fimmu.2019.03095
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
